Yosef Y. Tobi

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer”.

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Nature Communications(2021)10.1038/s41467-021-23912-4

N/A

1.1DataRank · unranked

34 citations

Adam J. Schoenfeld, Alex Makhnin, Yosef Y. Tobi, Yuli Wang, Heidie Frisco Cabanos +10 more

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100256

N/A

0.396DataRank · unranked

13 citations

Eusebio Manchado, Matthew J. Bott, Linda S. Ahn, Yosef Y. Tobi, Andy Ai Ni +14 more

In the SARS-CoV-2 Pandora Pandemic: Can the Stance of Premorbid Intestinal Innate Immune System as Measured by Fecal Adnab-9 Binding of p87:Blood Ferritin, Yielding the FERAD Ratio, Predict COVID-19 Susceptibility and Survival in a Prospective Population Database?

International Journal of Molecular Sciences(2023)10.3390/ijms24087536

N/A

0DataRank · unranked

7 citations

Martin H. Bluth, Noreen F. Rossi, Ereny Demian, Harvinder Talwar, Yosef Y. Tobi +5 more